|
Recent Developments |
|
28-JAN-19
Natco Pharma announced today that it has launched Valsartan-Sacubitril tablet at an affordable price, under its brand VALSAC. Valsartan-Sacubitril is a combination drug used for certain types of heart failure, and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.
11-JUN-18
Natco Pharma announced that it has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand PO... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 9674.10 | 6645.00 | 5720.40 | | Other Income | 139.30 | 135.50 | 157.10 | | Total Income | 9813.40 | 6780.50 | 5877.50 | | Cost of goods sold | 7402.90 | 4869.90 | 4357.50 | | OPBDIT | 2410.50 | 1910.60 | 1520.00 | | PAT | 1795.20 | 1529.20 | 1101.90 | | Gross Block | - | - | - | | Equity capital | 348.30 | 332.30 | 330.70 | | EPS (Rs.) | - | 46.17 | 34.49 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 14.20 - 49.63 | 11.31 - 25.43 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 24.6 | 28.2 | 25.9 | | Net margin (% of OI) | 18.3 | 22.6 | 18.7 |
|
|
Detailed Financials
|
|
|
|
|
